Net sales and operating result

The Services segment generated net sales of CHF 1,177.1 million in the first half of 2018, an increase of 0.9% compared to the prior-year period. This was achieved in an overall market whose growth (+3.6%, IQVIA, first half of 2018) was driven especially by the sales performance of hospitals (+6.5%, IQVIA, first half of 2018) as well as by high-priced special medications that are for the most part not supplied via wholesale but directly to specialist doctors (doctors: +2.4%, IQVIA, first half of 2018). At the same time, the federal price reduction measures, which were significantly higher than announced, and strong growth in generics also had an impact on the sales of Services.

The operating result (EBIT) declined by 22.1% to CHF 22.3 million due to one-off effects from the prior-year period totalling CHF 7.0 million that did not recur in the period under review (sale of rights of the medical practice software Triamed® and a non-operational building in Schönbühl). Excluding these one-off effects, EBIT rose by 2.8%.

Return on sales (ROS) was maintained at a high level of 1.9%. Investments in the first half of 2018 amounted to CHF 16.1 million and were used in particular to finance the new ERP software that is being rolled out progressively at Alloga and Galexis.


Net sales in million CHF


EBIT in million CHF


Number of employees


Galenica Ltd.

Untermattweg 8
3027 Bern

Tel. +41 58 852 81 11
Fax +41 58 852 81 12